Zenotech, Ranbaxy to partner on 11 generic oncology drugs

New York, June 7 - Zenotech Laboratories Ltd. and Ranbaxy Laboratories Ltd.'s Ranbaxy Pharmaceuticals Inc. announced a partnership to develop and submit for regulatory approval 11 generic oncology products for sale in the United States and Canada.

The combined branded sales of these products is $3.7 billion.

Zenotech, a Hyderabad, India, maker of specialty generic injectables, will develop and manufacture the products and Ranbaxy, a Mumbai, India, pharmaceutical company, will market them.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.